Drug Trial Radar · NCT07748728
TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
90
Planned (sponsor's estimate)
Start
Sep 18, 2026
Primary completion
Jul 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
Conditions
- Rheumatoid Arthritis (RA)
Interventions
TLL-018Drug
Treatment group: TLL-018 20 mg BID in Period 1 → TLL-018 20 mg BID in Period 2
PlaceboDrug
Placebo group: Placebo BID in Period 1 → TLL-018 20 mg BID in Period 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.